Topotecan treatment and its toxic effects on hematologic parameters and trace elements

Biological Trace Element Research

Volumn 124, Issue 2, 2008, Pages 129-134

  Bülbül Hızel, Selda ^a   Şanlı, Cihat ^a   Bayar Muluk, Nuray ^a   Albayrak, Meryem ^a   Özyazıcı, Ahmet ^a   Apan, Alpaslan ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Myelosuppression; Topotecan; Trace elements

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; COBALT; COPPER; DNA TOPOISOMERASE; HEMOGLOBIN; LEAD; SELENIUM; TOPOTECAN; TRACE ELEMENT; ZINC;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER PATIENT; CELL DEGENERATION; CELL MATURATION; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE COUNT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; LEUKOCYTE COUNT; MALE; NONHUMAN; RABBIT; SUPPLEMENTATION; THROMBOCYTE COUNT; ANIMAL; BLOOD; BONE MARROW; DIET SUPPLEMENTATION; HUMAN; METABOLISM; NEOPLASM; TIME;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; DIETARY SUPPLEMENTS; ERYTHROCYTES; HEMOGLOBINS; HUMANS; NEOPLASMS; RABBITS; TIME FACTORS; TOPOTECAN; TRACE ELEMENTS;

EID: 55549140844     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12011-008-8140-9     Document Type: Article

References (25)

1. RJ Cersosimo 1998 Topotekan: a new topoisomerase I inhibiting antineoplastic agent Ann Pharmacother 32 1334 1343 (Pubitemid 29013358)
2. HM Kantarjian M Beran A Ellis L Zwelling S O'Brien L Cazenave C Koller MB Rios W Plunkett MJ Keating 1993 Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia Blood 81 1146 1151 (Pubitemid 23067348)
3. EH Kraut J Crowley JL Wade LR Laufman M Alsina SA Taylor 1998 Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study J Clin Oncol 16 589 592 (Pubitemid 28135604)
4. RN Brogden LR Wiseman 1998 Topotecan. A review of its potential in advanced ovarian cancer Drugs 56 709 723 (Pubitemid 28488271)
5. CH Takimoto SG Arbuck 1997 Clinical status and optimal use of topotecan Oncology 11 1635 1646 (Pubitemid 27505664)
6. JF Heron 1998 Topotecan. An oncologist's view Oncologist 3 390 402 (Pubitemid 29009302)
7. UH Athale C Stewart JF Kuttesch A Moghrabi W Meyer C Pratt A Gajjar RL Heideman 2002 Phase I study of combination topotecan and carboplastin in pediatric solid tumors J Clin Oncol 20 88 95 (Pubitemid 34032600)
8. A Younes HA Preti FB Hagemeister P McLaughlin J Romaguera MA Rodriguez BI Samuels JL Palmer F Cabanillas 2001 Paclitaxel plus topotecan treatment for patients with relapse or refractory aggressive non-Hodgkin's lymphoma Ann Oncol 12 923 927 (Pubitemid 32725763)
9. SW Warmann J Fuchs L Wilkens KF Gratz D von Schweinitz H Mildenberger 2001 Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan Med Pediatr Oncol 37 449 454 (Pubitemid 33029639)
10. SZ Soffer E Kim JT Moore J Huang A Yokoi C Manley K O'Toole W Middlesworth C Stolar D Yamashiro J Kandel 2001 Novel use of an established agent: topotecan is anti-angiogenic in experimental Wilms tumor J Pediatr Surg 36 1781 1784 (Pubitemid 33131682)
11. CF Stewart SD Baker RL Heideman D Jones WR Crom C Pratt 1994 Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity J Clin Oncol 12 1946 1954 (Pubitemid 24349399)
12. JR Eckardt 2001 Feasibility of oral topotecan in previously untreated patient with small-cell lung cancer ineligible for standard therapy Oncology 61 42 46 (Pubitemid 33757976)
13. H Ozan F Özkalemkaş Ü Ozan K Özerkan T Bilgin F KüçükyIldIz 2001 Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan Eur J Gynaecol Oncol 22 463 465 (Pubitemid 34160739)
14. PJ O'Dwyer FB LaCreta NB Haas T Halbherr H Frucht E Goosenberg KS Yao 1994 Clinical, pharmacokinetic and biological studies of topotecan Cancer Chemother Pharmacol 34 46 52 (Pubitemid 24264044)
15. EK Rovinsky LB Grochow CB Hendricks DS Ettinger AA Forastiere LA Hurowitz WP McGuire SE Sartorius BG Lubejko SH Kaufmann 1992 Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor J Clin Oncol 10 647 656
16. J Lu C Jiang 2001 Antiangogenic activity of selenium in cancer chemoprevention: metabolite-specific effects Nutr Cancer 40 64 73 (Pubitemid 34037516)
17. 52nd WMA General Assembly 2000 World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects JAMA 284 3043 3049
18. CS Straathof MJ van den Bent WJ Loos CJ Vecht JH Schellens 1999 The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration J Neurooncol 42 17 122 (Pubitemid 29322146)
19. Hycamtin® (Topotecan Hydrochloride). Prescribing information. http://us.gsk.com/products/assets/us-hycamtin.pdf (Received online, April 3rd, 2008).
20. B Brenner A Zander M Cole A Gordon J Malfetano 1997 Comparison of axially and radially viewed inductively coupled plasma atomic emission spectrometry in terms of signal to background ratio and matrix effects J Anal At Spectrom 12 281 286 (Pubitemid 127589800)
21. W ten Bokkel Huinink J Carmichael D Armstrong A Gordon J Malfetano 1997 Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma Semin Oncol 24 5 19
22. JA Milner 1986 Inhibition of chemical carcinogenesis and tumorigenesis by selenium. Essential nutrients in carcinogenesis Adv Exp Med Biol 206 449 463
23. S HIzel T Coşkun S Berberoǧlu I Özalp G Tanyer 1994 Serum selenium levels in children relatIon to cancer Turk J Med Sci 21 249 252
24. X Jia N Li J Chen 2005 A subchronic toxicity study of elemental Nano-Se in Sprague-Dawley rats Life Sci 11 1989 2003 (Pubitemid 40222417)
25. M Fakih S Cao FA Durrani YM Rustum 2005 Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors Clin Colorectal Cancer 5 132 135